Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 110Carcinoma, Intraductal, Noninfiltrating 7Breast Carcinoma In Situ 6Neoplasms 4Neoplasm Metastasis 3Inflammatory Breast Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Infertility 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Breast Cancer Female 2Sleep Wake Disorders 1Quality of Life 1Pulmonary Fibrosis 1Prostatic Neoplasms 1Primary Breast Cancer 1Polycystic Ovary Syndrome 1Paget's Disease, Mammary 1Ovarian Neoplasms 1Obesity 1Neoplasm Recurrence, Local 1Liver Neoplasms 1Hot Flashes 1Fatigue 1Cardiotoxicity 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Carcinoma, Hepatocellular 1Breast Cancer Subjects 1

Interventions

Docetaxel 3Cyclophosphamide 3Paclitaxel 2Epirubicin 2Tamoxifen 1Fluorouracil 1Doxorubicin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Primary Breast Cancer × Tamoxifen × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡